Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895930586> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2895930586 endingPage "S764" @default.
- W2895930586 startingPage "S764" @default.
- W2895930586 abstract "Abstract Background In June 2018, the CDC reported that influenza vaccine effectiveness (VE) against A(H3N2) influenza virus for the 2017–2018 season was ~24%. This lower than expected VE was hypothesized to be partially related to genetic changes arising in the vaccine virus during passage in eggs. Flucelvax™ (Seqirus) is a cell culture-based inactivated influenza vaccine (ccIIV) which is not manufactured in eggs. We investigated whether the VE of ccIIV against influenza A differed from that of egg-based IIV (ebIIV) during the 2017–2018 influenza season. Methods The study included all Kaiser Permanente Northern California members aged 4–64 years. We identified all individuals who were positive for influenza by polymerase chain reaction (PCR). This cohort analysis estimated the relative VE of ccIIV vs. ebIIV by comparing the ccIIV vaccinees vs. the ebIIV vaccinees with respect to the risk of PCR-confirmed influenza. We separately estimated the absolute VE of ccIIV and ebIIV by comparing each group of vaccinees with unvaccinated individuals. We used Cox regression with a calendar timeline, stratified by birth year, and adjusted for facility, race, years of membership, prior season influenza vaccine, co-morbidities, and number of inpatient admits in the prior year. We calculated VE as 1 − hazard ratio (HR). Results Of the 3,015,891 members aged 4–64 years, 1,017,314 were vaccinated. Of these, 932,874 (91.7%) received ebIIV and 84,440 (8.3%) received ccIIV. Most ebIIV (86.2%) was trivalent. Comparing ccIIV with ebIIV, the adjusted relative VE against influenza A was 6.8% (95% CI: 11.2, 21.9; P = 0.43). The adjusted absolute VE vs. unvaccinated of ccIIV was 30.2% (95% CI: 17.1, 41.3; P < 0.0001) and of ebIIV was 17.9% (95% CI: 12.1, 23.3; P < 0.0001). Conclusion Both cell-culture and egg-based IIV vaccines showed relatively low effectiveness during the 2017–2018 influenza season in which A(H3N2) predominated. The findings of this study show there was no significant difference in the effectiveness of cell-culture IIV compared with egg-based IIVs. Improvements in influenza vaccines will require ongoing monitoring of vaccine effectiveness. Disclosures N. P. Klein, GSK: Investigator, Research support. Sanofi Pasteur: Investigator, Research support. Merck: Investigator, Research support. Pfizer: Investigator, Research support. Protein Science: Investigator, Research support. MedImmune: Investigator, Research support. Dynavax: Investigator, Research support." @default.
- W2895930586 created "2018-10-26" @default.
- W2895930586 creator A5016019091 @default.
- W2895930586 creator A5034478332 @default.
- W2895930586 creator A5043052005 @default.
- W2895930586 creator A5043424491 @default.
- W2895930586 creator A5049344401 @default.
- W2895930586 creator A5059023087 @default.
- W2895930586 creator A5065809957 @default.
- W2895930586 creator A5088198148 @default.
- W2895930586 date "2018-11-01" @default.
- W2895930586 modified "2023-09-26" @default.
- W2895930586 title "LB15. Vaccine Effectiveness of Flucelvax Relative to Inactivated Influenza Vaccine During the 2017–18 Influenza Season in Northern California" @default.
- W2895930586 doi "https://doi.org/10.1093/ofid/ofy229.2189" @default.
- W2895930586 hasPublicationYear "2018" @default.
- W2895930586 type Work @default.
- W2895930586 sameAs 2895930586 @default.
- W2895930586 citedByCount "10" @default.
- W2895930586 countsByYear W28959305862019 @default.
- W2895930586 countsByYear W28959305862020 @default.
- W2895930586 countsByYear W28959305862021 @default.
- W2895930586 countsByYear W28959305862022 @default.
- W2895930586 countsByYear W28959305862023 @default.
- W2895930586 crossrefType "journal-article" @default.
- W2895930586 hasAuthorship W2895930586A5016019091 @default.
- W2895930586 hasAuthorship W2895930586A5034478332 @default.
- W2895930586 hasAuthorship W2895930586A5043052005 @default.
- W2895930586 hasAuthorship W2895930586A5043424491 @default.
- W2895930586 hasAuthorship W2895930586A5049344401 @default.
- W2895930586 hasAuthorship W2895930586A5059023087 @default.
- W2895930586 hasAuthorship W2895930586A5065809957 @default.
- W2895930586 hasAuthorship W2895930586A5088198148 @default.
- W2895930586 hasBestOaLocation W28959305861 @default.
- W2895930586 hasConcept C126322002 @default.
- W2895930586 hasConcept C133239900 @default.
- W2895930586 hasConcept C144024400 @default.
- W2895930586 hasConcept C149923435 @default.
- W2895930586 hasConcept C159047783 @default.
- W2895930586 hasConcept C22070199 @default.
- W2895930586 hasConcept C2522874641 @default.
- W2895930586 hasConcept C2777546802 @default.
- W2895930586 hasConcept C2779134260 @default.
- W2895930586 hasConcept C2780689484 @default.
- W2895930586 hasConcept C2909469553 @default.
- W2895930586 hasConcept C2911097425 @default.
- W2895930586 hasConcept C3008058167 @default.
- W2895930586 hasConcept C3018751465 @default.
- W2895930586 hasConcept C524204448 @default.
- W2895930586 hasConcept C71924100 @default.
- W2895930586 hasConcept C72563966 @default.
- W2895930586 hasConceptScore W2895930586C126322002 @default.
- W2895930586 hasConceptScore W2895930586C133239900 @default.
- W2895930586 hasConceptScore W2895930586C144024400 @default.
- W2895930586 hasConceptScore W2895930586C149923435 @default.
- W2895930586 hasConceptScore W2895930586C159047783 @default.
- W2895930586 hasConceptScore W2895930586C22070199 @default.
- W2895930586 hasConceptScore W2895930586C2522874641 @default.
- W2895930586 hasConceptScore W2895930586C2777546802 @default.
- W2895930586 hasConceptScore W2895930586C2779134260 @default.
- W2895930586 hasConceptScore W2895930586C2780689484 @default.
- W2895930586 hasConceptScore W2895930586C2909469553 @default.
- W2895930586 hasConceptScore W2895930586C2911097425 @default.
- W2895930586 hasConceptScore W2895930586C3008058167 @default.
- W2895930586 hasConceptScore W2895930586C3018751465 @default.
- W2895930586 hasConceptScore W2895930586C524204448 @default.
- W2895930586 hasConceptScore W2895930586C71924100 @default.
- W2895930586 hasConceptScore W2895930586C72563966 @default.
- W2895930586 hasIssue "suppl_1" @default.
- W2895930586 hasLocation W28959305861 @default.
- W2895930586 hasLocation W28959305862 @default.
- W2895930586 hasLocation W28959305863 @default.
- W2895930586 hasOpenAccess W2895930586 @default.
- W2895930586 hasPrimaryLocation W28959305861 @default.
- W2895930586 hasRelatedWork W147953552 @default.
- W2895930586 hasRelatedWork W2048194595 @default.
- W2895930586 hasRelatedWork W2068741835 @default.
- W2895930586 hasRelatedWork W2287377033 @default.
- W2895930586 hasRelatedWork W2524712953 @default.
- W2895930586 hasRelatedWork W2791290311 @default.
- W2895930586 hasRelatedWork W2890492715 @default.
- W2895930586 hasRelatedWork W2979405251 @default.
- W2895930586 hasRelatedWork W4293102569 @default.
- W2895930586 hasRelatedWork W4298098245 @default.
- W2895930586 hasVolume "5" @default.
- W2895930586 isParatext "false" @default.
- W2895930586 isRetracted "false" @default.
- W2895930586 magId "2895930586" @default.
- W2895930586 workType "article" @default.